| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
An immunoassay for the measurement of sirolimus
|
Jones, Kirsty
|
|
2000
|
|
S2 |
p. B49-B61
nvt p.
|
artikel
|
| 2 |
An immunophilin-binding assay for sirolimus
|
Davis, Diane L.
|
|
2000
|
|
S2 |
p. B62-B70
nvt p.
|
artikel
|
| 3 |
Antiplatelet therapy in atherosclerotic cardiovascular disease
|
Gonzalez, Edgar R.
|
|
1998
|
|
S2 |
p. B18-B41
nvt p.
|
artikel
|
| 4 |
A phase II trial and quality-of-life analysis of a 5-day regimen of oral 5-fluorouracil bracketed by a 7-day regimen of oral eniluracil in untreated patients with unresectable or metastatic colorectal carcinoma
|
Hobday, TimothyJ.
|
|
2002
|
|
S2 |
p. 47-48
2 p.
|
artikel
|
| 5 |
A practical guide to the analysis of sirolimus using high-performance liquid chromatography with ultraviolet detection
|
Napoli, Kimberly L.
|
|
2000
|
|
S2 |
p. B14-B24
nvt p.
|
artikel
|
| 6 |
A randomized assessment of three quality-of-life questionnaires for patients with prostate cancer undergoing different radiation treatments
|
Senter, KimberlyK.
|
|
2002
|
|
S2 |
p. 31-33
3 p.
|
artikel
|
| 7 |
A rasch analysis of the functional scales of the European Organization for Research and Treatment of Cancer QLQ-C30 and the implications for clinical significance
|
Smith, AdamB.
|
|
2002
|
|
S2 |
p. 34-35
2 p.
|
artikel
|
| 8 |
Assessing meaningful change over time in quality of life: A user's guide for clinicians
|
Sprangers, MirjamA.G.
|
|
2002
|
|
S2 |
p. 8-
1 p.
|
artikel
|
| 9 |
Assessing the clinical significance of quality-of-life measures in oncology research: State of the science
|
Sloan, Jeff A
|
|
2002
|
|
S2 |
p. 1-4
4 p.
|
artikel
|
| 10 |
Assessing the clinical significance of single items relative to summated scores
|
Sloan, JeffA.
|
|
2002
|
|
S2 |
p. 6-7
2 p.
|
artikel
|
| 11 |
Assessing the Role of Biphasic Insulin Aspart 30 as an Effective and Tolerable Front-Line Therapy for Type 2 Diabetes
|
Garber, Alan J.
|
|
2005
|
|
S2 |
p. S39-S41
3 p.
|
artikel
|
| 12 |
Assessment of pain and somatosensory function in fabry disease: Early diagnosis
|
Maag, Rainer
|
|
2008
|
|
S2 |
p. S52-S53
2 p.
|
artikel
|
| 13 |
Assessment of palliation in patients with lung cancer: Comparisons between patient symptom diary scores and “minimum clinical change” in quality-of-life scores
|
Brundage, MichaelD.
|
|
2002
|
|
S2 |
p. 23-24
2 p.
|
artikel
|
| 14 |
Atherosclerotic disease
|
Ferguson III, JamesJ.
|
|
1998
|
|
S2 |
p. B1-
1 p.
|
artikel
|
| 15 |
Basic research: Metabolism during exercise in Pompe disease
|
Preisler, Nicolai
|
|
2010
|
|
S2 |
p. S60-S61
2 p.
|
artikel
|
| 16 |
Biphasic insulin aspart 30: Literature review of adverse events associated with treatment
|
Davidson, Jaime
|
|
2005
|
|
S2 |
p. S75-S88
14 p.
|
artikel
|
| 17 |
Cardiac aspects in infants with Pompe disease: Antenatal diagnosis by fetal echocardiography improves outcome
|
Hamdan, Mohamed A.
|
|
2010
|
|
S2 |
p. S48-
1 p.
|
artikel
|
| 18 |
Cerebral vessel involvement in Pompe disease
|
Laforêt, Pascal
|
|
2010
|
|
S2 |
p. S51-
1 p.
|
artikel
|
| 19 |
Challenges in adolescents: Growth and scoliosis
|
Bembi, Bruno
|
|
2010
|
|
S2 |
p. S41-
1 p.
|
artikel
|
| 20 |
Chaperone therapy
|
Parenti, Giancarlo
|
|
2010
|
|
S2 |
p. S58-S59
2 p.
|
artikel
|
| 21 |
Clarifying the significance of treatment effects on quality-of-life dimensions using structural equation modeling: Example from peripheral arterial obstructive diseases
|
Marquis, Patrick
|
|
2002
|
|
S2 |
p. 37-
1 p.
|
artikel
|
| 22 |
Clinical benefit in patients with cancer of the pancreas: How does it compare with clinically significant changes in quality-of-life scores?
|
Bezjak, Andrea
|
|
2002
|
|
S2 |
p. 12-14
3 p.
|
artikel
|
| 23 |
Clinical experience, implications, and expectations of treatment with alglucosidase alfa in infants
|
Nicolino, Marc
|
|
2010
|
|
S2 |
p. S57-
1 p.
|
artikel
|
| 24 |
Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study
|
Remuzzi, Giuseppe
|
|
2007
|
|
S2 |
p. S64-S72
9 p.
|
artikel
|
| 25 |
Clinical pharmacokinetics and therapeutic drug monitoring of sirolimus
|
MacDonald, Allan
|
|
2000
|
|
S2 |
p. B101-B121
nvt p.
|
artikel
|
| 26 |
Clinical practice and guidelines in Europe for the treatment of hypertension, with a focus on patients with diabetes mellitus
|
Zanchetti, Alberto
|
|
2007
|
|
S2 |
p. S44-S53
10 p.
|
artikel
|
| 27 |
Clinical safety and efficacy of clopidogrel-Implications of the clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE) study for future management of atherosclerotic disease
|
Ferguson III, James J.
|
|
1998
|
|
S2 |
p. B42-B53
nvt p.
|
artikel
|
| 28 |
Clinical significance of changes in quality-of-life scores during neoadjuvant treatment of esophageal cancer
|
Blazeby, JaneM.
|
|
2002
|
|
S2 |
p. 38-39
2 p.
|
artikel
|
| 29 |
Clinical significance of quality of life: The patient advocate perspective
|
Chauhan, Cynthia
|
|
2002
|
|
S2 |
p. 30-
1 p.
|
artikel
|
| 30 |
Cochlear system and hearing deficits
|
van der Ploeg, Ans
|
|
2010
|
|
S2 |
p. S68-
1 p.
|
artikel
|
| 31 |
Comorbidity of diabetes mellitus and hypertension in the clinical setting: A review of prevalence, pathophysiology, and treatment perspectives
|
Bretzel, Reinhard G.
|
|
2007
|
|
S2 |
p. S35-S43
9 p.
|
artikel
|
| 32 |
Concluding remarks
|
Chapel, Helen
|
|
1996
|
|
S2 |
p. 137-139
3 p.
|
artikel
|
| 33 |
Confirmatory factor analysis and clinical significance of the illness intrusiveness ratings scale in men and women with common cancer diagnoses
|
Devins, GeraldM.
|
|
2002
|
|
S2 |
p. 25-26
2 p.
|
artikel
|
| 34 |
Correlations between target scores and anchor ratings on a health transition questionnaire
|
Osoba, David
|
|
2002
|
|
S2 |
p. 26-27
2 p.
|
artikel
|
| 35 |
Differential diagnosis and misdiagnosis of Pompe disease in adults
|
Straub, Volker
|
|
2010
|
|
S2 |
p. S67-
1 p.
|
artikel
|
| 36 |
Dried blood spots as a sample type in acid α-glucosidase enzyme assays for Pompe disease
|
Lukacs, Zoltan
|
|
2010
|
|
S2 |
p. S53-S54
2 p.
|
artikel
|
| 37 |
Early detection and treatment of fabry disease
|
Breunig, Frank
|
|
2008
|
|
S2 |
p. S45-
1 p.
|
artikel
|
| 38 |
Early detection of fabry disease: Cardiac cases
|
Weidemann, Frank
|
|
2008
|
|
S2 |
p. S46-
1 p.
|
artikel
|
| 39 |
Effectiveness and tolerability of pharmacologic and combined interventions for reducing injection pain during routine childhood immunizations: Systematic review and meta-analyses
|
Shah, Vibhuti
|
|
2009
|
|
S2 |
p. S104-S151
48 p.
|
artikel
|
| 40 |
Efficacy of biphasic insulin aspart in patients with type 2 diabetes
|
Halimi, Serge
|
|
2005
|
|
S2 |
p. S57-S74
18 p.
|
artikel
|
| 41 |
Exercise therapy in muscle disease: Perspectives for Pompe disease
|
Vissing, John
|
|
2010
|
|
S2 |
p. S69-
1 p.
|
artikel
|
| 42 |
Fabry disease—whom to treat and when
|
Mehta, Atul
|
|
2008
|
|
S2 |
p. S43-S44
2 p.
|
artikel
|
| 43 |
FlexPen®: Addressing issues of confidence andconvenience in insulin delivery
|
Korytkowski, Mary
|
|
2005
|
|
S2 |
p. S89-S100
12 p.
|
artikel
|
| 44 |
Foreword
|
Taddio, Anna
|
|
2009
|
|
S2 |
p. S47-
1 p.
|
artikel
|
| 45 |
Foreword
|
Wanner, Christoph
|
|
2008
|
|
S2 |
p. S39-
1 p.
|
artikel
|
| 46 |
Gammagard® and reported hepatitis C virus episodes
|
Gomperts, Edward D.
|
|
1996
|
|
S2 |
p. 3-8
6 p.
|
artikel
|
| 47 |
Genetics and epidemiology of Pompe disease
|
Stewart, Fiona
|
|
2010
|
|
S2 |
p. S66-
1 p.
|
artikel
|
| 48 |
Genetic suppression of autophagy dramatically enhances enzyme replacement therapy in murine Pompe disease
|
Raben, Nina
|
|
2010
|
|
S2 |
p. S62-
1 p.
|
artikel
|
| 49 |
Group versus individual approaches to understanding the clinical significance of differences or changes in quality of life
|
Cella, David
|
|
2002
|
|
S2 |
p. 6-
1 p.
|
artikel
|
| 50 |
Hepatitis C virus infection: clinical aspects and treatment with interferon alfa
|
Jonas, Maureen M.
|
|
1996
|
|
S2 |
p. 110-125
16 p.
|
artikel
|
| 51 |
Hepatitis C virus infection in Italian patients with hypogammaglobulinemia
|
Quinti, Isabella
|
|
1996
|
|
S2 |
p. 96-107
12 p.
|
artikel
|
| 52 |
Hepatitis C virus screening and intravenous immunoglobulin safety in Japan
|
Nishioka, Kusuya
|
|
1996
|
|
S2 |
p. 83-92
10 p.
|
artikel
|
| 53 |
Immunological aspects of treatment of Pompe disease
|
Kishnani, Priya S.
|
|
2010
|
|
S2 |
p. S49-S50
2 p.
|
artikel
|
| 54 |
Implications of early renal changes in fabry disease
|
Mauer, Michael
|
|
2008
|
|
S2 |
p. S40-
1 p.
|
artikel
|
| 55 |
Improving the quality of life for patients with cancer through the cancer supportive care program and web site
|
Rosenbaum, ErnestH.
|
|
2002
|
|
S2 |
p. 11-12
2 p.
|
artikel
|
| 56 |
Inadequate pain management during routine childhood immunizations: The nerve of it
|
Taddio, Anna
|
|
2009
|
|
S2 |
p. S152-S167
16 p.
|
artikel
|
| 57 |
Insulin resistance: From predisposing factor to therapeutic target in type 2 diabetes
|
Henry, Robert R.
|
|
2003
|
|
S2 |
p. B47-B63
nvt p.
|
artikel
|
| 58 |
Interpretation of change and longitudinal validity of the quality of life for respiratory illness questionnaire in inpatient pulmonary rehabilitation
|
van Stel, HenkF.
|
|
2002
|
|
S2 |
p. 17-18
2 p.
|
artikel
|
| 59 |
Interpretation of quality-of-life data from a clinician's point of view: Getting to the clinical part of clinically meaningful change
|
Dennison, CherylR.
|
|
2002
|
|
S2 |
p. 40-41
2 p.
|
artikel
|
| 60 |
Intravenous immunoglobulin and hepatitis C virus: an overview of transmission episodes with emphasis on manufacturing data
|
Yap, Peng Lee
|
|
1996
|
|
S2 |
p. 43-58
16 p.
|
artikel
|
| 61 |
Intravenous immunoglobulin and hepatitis C virus: the boston episode
|
Schneider, Lynda C.
|
|
1996
|
|
S2 |
p. 108-109
2 p.
|
artikel
|
| 62 |
Intravenous immunoglobulin and hepatitis C virus: the British episode
|
Healey, Christopher
|
|
1996
|
|
S2 |
p. 93-95
3 p.
|
artikel
|
| 63 |
Intravenous Immunoglobulin and hepatitis C virus: the scandinavian experience
|
Björkander, Janne
|
|
1996
|
|
S2 |
p. 73-82
10 p.
|
artikel
|
| 64 |
Introduction
|
Boyle, Patrick J.
|
|
2003
|
|
S2 |
p. B1-B3
nvt p.
|
artikel
|
| 65 |
Introduction
|
Geha, Raif S.
|
|
1996
|
|
S2 |
p. 1-2
2 p.
|
artikel
|
| 66 |
Introduction and overview
|
Shaw, Leslie M.
|
|
2000
|
|
S2 |
p. B1-B13
nvt p.
|
artikel
|
| 67 |
Long-term quality of life associated with a chemotherapy-based regimen for newly diagnosed central nervous system germ cell tumors: The first international cooperative trial
|
Sands, StephenA.
|
|
2002
|
|
S2 |
p. 28-
1 p.
|
artikel
|
| 68 |
Meaningful change in cancer-specific quality-of-life scores: Differences between improvement and worsening
|
Dineen, Kelly
|
|
2002
|
|
S2 |
p. 41-42
2 p.
|
artikel
|
| 69 |
Measurement of fatigue: Determining minimally important clinical differences
|
Schwartz, AnnaL.
|
|
2002
|
|
S2 |
p. 14-16
3 p.
|
artikel
|
| 70 |
Measurement of sirolimus in whole blood using high-performance liquid chromatography with ultraviolet detection
|
Holt, David W.
|
|
2000
|
|
S2 |
p. B38-B48
nvt p.
|
artikel
|
| 71 |
Measuring the quality of life of patients with breast cancer treated with breast-conserving techniques
|
Hardy, MariaM.
|
|
2002
|
|
S2 |
p. 30-31
2 p.
|
artikel
|
| 72 |
Methods for explaining the clinical significance of health status measures
|
Guyatt, GordonH.
|
|
2002
|
|
S2 |
p. 5-
1 p.
|
artikel
|
| 73 |
Minimal important difference: Can we predict its magnitude?
|
Ringash, JolieG.
|
|
2002
|
|
S2 |
p. 22-23
2 p.
|
artikel
|
| 74 |
Multicenter retrospective assessment of thiazolidinedione monotherapy and combination therapy in patients with type 2 diabetes: Comparative subgroup analyses of glycemic control and blood lipid levels
|
Olansky, Leann
|
|
2003
|
|
S2 |
p. B64-B80
nvt p.
|
artikel
|
| 75 |
Neurology in fabry disease
|
Torvin Møller, Anette
|
|
2008
|
|
S2 |
p. S47-S49
3 p.
|
artikel
|
| 76 |
Newborn screening in fabry disease: What can be achieved with early diagnosis?
|
Bodamer, Olaf A.
|
|
2008
|
|
S2 |
p. S41-
1 p.
|
artikel
|
| 77 |
New developments in the treatment of Pompe disease
|
Mattaliano, Robert J.
|
|
2010
|
|
S2 |
p. S55-S56
2 p.
|
artikel
|
| 78 |
[No title]
|
Müller-Felber, Wolfgang
|
|
2010
|
|
S2 |
p. S39-S40
2 p.
|
artikel
|
| 79 |
Overview of atherosclerosis
|
Kannel, William B.
|
|
1998
|
|
S2 |
p. B2-B17
nvt p.
|
artikel
|
| 80 |
Pancreatic beta-cell loss and preservation in type 2 diabetes
|
Buchanan, Thomas A.
|
|
2003
|
|
S2 |
p. B32-B46
nvt p.
|
artikel
|
| 81 |
Partnering with the Pompe disease patient community
|
Schaller, Thomas
|
|
2010
|
|
S2 |
p. S65-
1 p.
|
artikel
|
| 82 |
Patient, clinician, and population perspectives on determining the clinical significance of quality-of-life scores
|
Frost, MarleneH.
|
|
2002
|
|
S2 |
p. 7-8
2 p.
|
artikel
|
| 83 |
Patterns of muscle involvement in Pompe disease: A whole-body MRI study
|
Carlier, Robert Yves
|
|
2010
|
|
S2 |
p. S42-S43
2 p.
|
artikel
|
| 84 |
Physical interventions and injection techniques for reducing injection pain during routine childhood immunizations: Systematic review of randomized controlled trials and quasi-randomized controlled trials
|
Taddio, Anna
|
|
2009
|
|
S2 |
p. S48-S76
29 p.
|
artikel
|
| 85 |
Pompe disease: A clinical spectrum
|
Deegan, Patrick
|
|
2010
|
|
S2 |
p. S46-S47
2 p.
|
artikel
|
| 86 |
Poster abstracts
|
|
|
2010
|
|
S2 |
p. S71-S85
15 p.
|
artikel
|
| 87 |
Poster Abstracts
|
|
|
2008
|
|
S2 |
p. S55-S74
20 p.
|
artikel
|
| 88 |
Postprandial glucose regulation: New data andnew implications
|
Leiter, Lawrence A.
|
|
2005
|
|
S2 |
p. S42-S56
15 p.
|
artikel
|
| 89 |
Pregnancy outcome in a Pompe disease patient treated with enzyme replacement therapy
|
Lindberg, Christopher
|
|
2010
|
|
S2 |
p. S52-
1 p.
|
artikel
|
| 90 |
Prevalance of hepatitis C virus in plasma pools and the effectiveness of cold ethanol fractionation
|
Scheiblauer, Heiner
|
|
1996
|
|
S2 |
p. 59-70
12 p.
|
artikel
|
| 91 |
Proficiency-testing issues relating to sirolimus
|
Jones, Kirsty
|
|
2000
|
|
S2 |
p. B122-B132
nvt p.
|
artikel
|
| 92 |
Prominence of glomerular and vascular changes in renal biopsies in children and adolescents with fabry disease and microalbuminuria
|
Tøndel, Camilla
|
|
2008
|
|
S2 |
p. S42-
1 p.
|
artikel
|
| 93 |
Psychological interventions for reducing pain and distress during routine childhood immunizations: A systematic review
|
Chambers, Christine T.
|
|
2009
|
|
S2 |
p. S77-S103
27 p.
|
artikel
|
| 94 |
Quality-of-life and behavioral follow-up study of pediatric craniopharyngioma survivors
|
Sands, StephenA.
|
|
2002
|
|
S2 |
p. 29-
1 p.
|
artikel
|
| 95 |
Quality-of-life changes during the first cycle of myelosuppressive chemotherapy
|
Fortner, BarryV.
|
|
2002
|
|
S2 |
p. 46-47
2 p.
|
artikel
|
| 96 |
Quality-of-life measures as leading indicators of adverse clinical events after bone marrow and stem cell transplantation
|
Bush, NigelE.
|
|
2002
|
|
S2 |
p. 9-11
3 p.
|
artikel
|
| 97 |
Quality of life of cancer patients as reported in a tumor registry follow-up
|
Harris, MarcellineR.
|
|
2002
|
|
S2 |
p. 43-44
2 p.
|
artikel
|
| 98 |
Rationale for use of the fixed combination of delapril and manidipine in the treatment of hypertension in patients with diabetes mellitus
|
Fogari, Roberto
|
|
2007
|
|
S2 |
p. S54-S63
10 p.
|
artikel
|
| 99 |
Requirements for therapeutic Drug monitoring of sirolimus, an immunosuppressive agent used in renal transplantation
|
Aspeslet, Launa J.
|
|
2000
|
|
S2 |
p. B86-B92
nvt p.
|
artikel
|
| 100 |
Response shift in individualized quality of life in patients with advanced prostate cancer
|
Rees, JonathanE.
|
|
2002
|
|
S2 |
p. 33-34
2 p.
|
artikel
|
| 101 |
Safety of intravenous immunoglobulin with regard to hepatitis c virus
|
Yu, Mei-ying W.
|
|
1996
|
|
S2 |
p. 71-72
2 p.
|
artikel
|
| 102 |
Secondary immunodeficiencies and stem cell transplantation: issues of administration and safety of intravenous immunoglobulin
|
Sullivan, Keith M.
|
|
1996
|
|
S2 |
p. 126-136
11 p.
|
artikel
|
| 103 |
The cancer outcomes measurement working group: Evaluating the state of the science and developing recommendations for improving outcomes assessment in cancer
|
Snyder, Claire
|
|
2002
|
|
S2 |
p. 21-
1 p.
|
artikel
|
| 104 |
The clinical significance of QOL results: Practical considerations for specific audiences
|
Symonds, Tara
|
|
2002
|
|
S2 |
p. 8-9
2 p.
|
artikel
|
| 105 |
The immunogenicity of therapeutic proteins and the fabry antibody standardization initiative
|
Schellekens, Huub
|
|
2008
|
|
S2 |
p. S50-S51
2 p.
|
artikel
|
| 106 |
The Pompe Registry
|
Roberts, Mark
|
|
2010
|
|
S2 |
p. S63-S64
2 p.
|
artikel
|
| 107 |
The quantification of sirolimus by high-performance liquid chromatography-tandem mass spectrometry and microparticle enzyme immunoassay in renal transplant recipients
|
Salm, Paul
|
|
2000
|
|
S2 |
p. B71-B85
nvt p.
|
artikel
|
| 108 |
Therapeutic monitoring of sirolimus in human whole-blood samples by high-performance liquid chromatography
|
Maleki, Saber
|
|
2000
|
|
S2 |
p. B25-B37
nvt p.
|
artikel
|
| 109 |
Toxicity and efficacy of sirolimus: Relationship to whole-blood concentrations
|
Meier-Kriesche, Herwig-Ulf
|
|
2000
|
|
S2 |
p. B93-B100
nvt p.
|
artikel
|
| 110 |
Type 2 diabetes, cardiovascular risk, and the link to insulin resistance
|
Stolar, Mark W.
|
|
2003
|
|
S2 |
p. B4-B31
nvt p.
|
artikel
|
| 111 |
Unsuspected manifestations of Pompe disease: Focus on respiratory disturbances
|
Confalonieri, Marco
|
|
2010
|
|
S2 |
p. S44-S45
2 p.
|
artikel
|
| 112 |
Use of event charts for summarizing clinically significant changes in oncology quality-of-life data
|
Atherton, PamelaJ.
|
|
2002
|
|
S2 |
p. 48-49
2 p.
|
artikel
|
| 113 |
Use of individual quality-of-life data in oncology consultations: Approach to interpretation of individual results and physicians' feedback on clinical usefulness
|
Velikova, GalinaI.
|
|
2002
|
|
S2 |
p. 35-36
2 p.
|
artikel
|
| 114 |
Using patient- and clinician-rated anchors to evaluate change on the functional assessment of cancer therapy—biologic response modifiers
|
Hahn, ElizabethA.
|
|
2002
|
|
S2 |
p. 19-20
2 p.
|
artikel
|
| 115 |
Viral safety of blood derivatives: an overview
|
Horaud, Florian
|
|
1996
|
|
S2 |
p. 37-42
6 p.
|
artikel
|
| 116 |
Virology of hepatitis C virus
|
Simmonds, Peter
|
|
1996
|
|
S2 |
p. 9-36
28 p.
|
artikel
|
| 117 |
What does it all mean? Using health-related quality-of-life data to interpret treatment outcomes
|
Leidy, NancyK.
|
|
2002
|
|
S2 |
p. 39-40
2 p.
|
artikel
|
| 118 |
What is measured by the schedule for the evaluation of individual quality of life-direct weighting?
|
Vielhaber, Annette
|
|
2002
|
|
S2 |
p. 44-45
2 p.
|
artikel
|
| 119 |
What is the relationship between clinical and health-related quality-of-life measures?
|
Hagan, Michael
|
|
2002
|
|
S2 |
p. 16-17
2 p.
|
artikel
|
Tijdschrift beschrijving